|
|
|
|
| LEADER |
02824nam a22005415i 4500 |
| 001 |
978-3-319-50693-7 |
| 003 |
DE-He213 |
| 005 |
20170209141655.0 |
| 007 |
cr nn 008mamaa |
| 008 |
170209s2017 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319506937
|9 978-3-319-50693-7
|
| 024 |
7 |
|
|a 10.1007/978-3-319-50693-7
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RM1-950
|
| 072 |
|
7 |
|a MMG
|2 bicssc
|
| 072 |
|
7 |
|a MED071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615
|2 23
|
| 245 |
1 |
0 |
|a Free Fatty Acid Receptors
|h [electronic resource] /
|c edited by Graeme Milligan, Ikuo Kimura.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2017.
|
| 300 |
|
|
|a VIII, 256 p. 70 illus.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Handbook of Experimental Pharmacology,
|x 0171-2004 ;
|v 236
|
| 505 |
0 |
|
|a Ligands at Free Fatty Acid Receptor 1 (GPR40) -- Ligands at Free Fatty Acid Receptor 2/3 (GPR43)/GPR41 -- Ligands at GPR84 -- Ligands at Free Fatty Acid Receptor 4 (GPR120) -- Homology modelling of FFA receptors -- Sensors for FFA receptors -- Key questions for translation of FFA receptors from pharmacology to medicines -- Polymorphic variation in FFA receptors. Functions and consequences -- The role and future of FFA1 as a therapeutic target -- Gut hormone regulation and secretion via FFA1 and FFA4 -- The role of FFA2 and FFA3 in metabolic regulation -- Anti-inflammatory and insulin sensitizing effects of free fatty acid receptors -- Free Fatty Acid receptors and cancer. .
|
| 520 |
|
|
|a This book highlights the important role free fatty acids (FFA) play as potential drug targets. While FFA have long been considered byproducts of cell metabolism, they are now recognized as ligands that regulate cell and tissue function via G-protein-coupled receptors. At least three receptors have been identified for which FFA appear to be the endogenous ligands.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Human physiology.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Diabetes.
|
| 650 |
|
0 |
|a Medical biochemistry.
|
| 650 |
|
0 |
|a Systems biology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Human Physiology.
|
| 650 |
2 |
4 |
|a Diabetes.
|
| 650 |
2 |
4 |
|a Systems Biology.
|
| 650 |
2 |
4 |
|a Medical Biochemistry.
|
| 700 |
1 |
|
|a Milligan, Graeme.
|e editor.
|
| 700 |
1 |
|
|a Kimura, Ikuo.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319506920
|
| 830 |
|
0 |
|a Handbook of Experimental Pharmacology,
|x 0171-2004 ;
|v 236
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-50693-7
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
